Scinomed Ltd - Accounts to registrar (filleted) - small 22.3

Scinomed Ltd - Accounts to registrar (filleted) - small 22.3


IRIS Accounts Production v22.4.0.132 06509477 Board of Directors 1.1.21 29.12.21 29.12.21 20/3/2022 true false true false false false true false Auditors Opinion iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure065094772020-12-31065094772021-12-29065094772021-01-012021-12-29065094772019-12-31065094772020-01-012020-12-31065094772020-12-3106509477ns16:EnglandWales2021-01-012021-12-2906509477ns15:PoundSterling2021-01-012021-12-2906509477ns11:Director12021-01-012021-12-2906509477ns11:PrivateLimitedCompanyLtd2021-01-012021-12-2906509477ns11:SmallEntities2021-01-012021-12-2906509477ns11:Audited2021-01-012021-12-2906509477ns11:SmallCompaniesRegimeForDirectorsReport2021-01-012021-12-2906509477ns11:SmallCompaniesRegimeForAccounts2021-01-012021-12-2906509477ns11:FullAccounts2021-01-012021-12-290650947712021-01-012021-12-2906509477ns11:Director32021-01-012021-12-2906509477ns11:Director42021-01-012021-12-2906509477ns11:RegisteredOffice2021-01-012021-12-2906509477ns6:CurrentFinancialInstruments2021-12-2906509477ns6:CurrentFinancialInstruments2020-12-3106509477ns6:Non-currentFinancialInstruments2021-12-2906509477ns6:Non-currentFinancialInstruments2020-12-3106509477ns6:ShareCapital2021-12-2906509477ns6:ShareCapital2020-12-3106509477ns6:SharePremium2021-12-2906509477ns6:SharePremium2020-12-3106509477ns6:RetainedEarningsAccumulatedLosses2021-12-2906509477ns6:RetainedEarningsAccumulatedLosses2020-12-3106509477ns6:DevelopmentCostsCapitalisedDevelopmentExpenditure2021-01-012021-12-2906509477ns6:ComputerSoftware2021-01-012021-12-2906509477ns6:LeaseholdImprovements2021-01-012021-12-2906509477ns6:PlantMachinery2021-01-012021-12-2906509477ns6:FurnitureFittings2021-01-012021-12-2906509477ns6:ComputerEquipment2021-01-012021-12-2906509477ns6:IntangibleAssetsOtherThanGoodwill2020-12-3106509477ns6:IntangibleAssetsOtherThanGoodwill2021-01-012021-12-2906509477ns6:IntangibleAssetsOtherThanGoodwill2021-12-2906509477ns6:IntangibleAssetsOtherThanGoodwill2020-12-3106509477ns6:LeaseholdImprovements2020-12-3106509477ns6:PlantMachinery2020-12-3106509477ns6:FurnitureFittings2020-12-3106509477ns6:ComputerEquipment2020-12-3106509477ns6:LeaseholdImprovements2021-12-2906509477ns6:PlantMachinery2021-12-2906509477ns6:FurnitureFittings2021-12-2906509477ns6:ComputerEquipment2021-12-2906509477ns6:LeaseholdImprovements2020-12-3106509477ns6:PlantMachinery2020-12-3106509477ns6:FurnitureFittings2020-12-3106509477ns6:ComputerEquipment2020-12-3106509477ns6:CostValuation2020-12-3106509477ns6:WithinOneYearns6:CurrentFinancialInstruments2021-12-2906509477ns6:WithinOneYearns6:CurrentFinancialInstruments2020-12-3106509477ns6:Non-currentFinancialInstruments2021-01-012021-12-290650947712021-01-012021-12-29
REGISTERED NUMBER: 06509477 (England and Wales)















SCINOMED LTD

FINANCIAL STATEMENTS

FOR THE PERIOD

1 JANUARY 2021 TO 29 DECEMBER 2021






SCINOMED LTD (REGISTERED NUMBER: 06509477)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE PERIOD 1 JANUARY 2021 TO 29 DECEMBER 2021




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


SCINOMED LTD

COMPANY INFORMATION
FOR THE PERIOD 1 JANUARY 2021 TO 29 DECEMBER 2021







DIRECTORS: Mr A P Lane
Mr M Hauck
Mr J Simkins





REGISTERED OFFICE: Windsor House
Cornwall Road
Harrogate
HG1 2PW





REGISTERED NUMBER: 06509477 (England and Wales)





AUDITORS: DSC Accountants Ltd
Chartered Accountants
Statutory Auditors
Tattersall House
East Parade
Harrogate
North Yorkshire
HG1 5LT

SCINOMED LTD (REGISTERED NUMBER: 06509477)

BALANCE SHEET
29 DECEMBER 2021

2021 2020
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 717,848 721,891
Tangible assets 5 77,085 711,342
Investments 6 1,812,845 1,812,845
2,607,778 3,246,078

CURRENT ASSETS
Stocks 836,358 1,122,529
Debtors 7 3,954,934 3,530,622
Prepayments and accrued income 3,164,076 2,984,016
Cash at bank and in hand 1,126,089 91,883
9,081,457 7,729,050
CREDITORS
Amounts falling due within one year 8 1,157,626 1,315,314
NET CURRENT ASSETS 7,923,831 6,413,736
TOTAL ASSETS LESS CURRENT
LIABILITIES

10,531,609

9,659,814

CREDITORS
Amounts falling due after more than one year 9 (18,401,701 ) (16,224,528 )

ACCRUALS AND DEFERRED INCOME (22,999 ) (574,947 )
NET LIABILITIES (7,893,091 ) (7,139,661 )

CAPITAL AND RESERVES
Called up share capital 250,000 200,000
Share premium 1,265,000 315,000
Retained earnings (9,408,091 ) (7,654,661 )
SHAREHOLDERS' FUNDS (7,893,091 ) (7,139,661 )

SCINOMED LTD (REGISTERED NUMBER: 06509477)

BALANCE SHEET - continued
29 DECEMBER 2021


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 20 March 2022 and were signed on its behalf by:





Mr A P Lane - Director


SCINOMED LTD (REGISTERED NUMBER: 06509477)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD 1 JANUARY 2021 TO 29 DECEMBER 2021

1. STATUTORY INFORMATION

Scinomed Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Preparation of consolidated financial statements
The financial statements contain information about Scinomed Ltd as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Going concern
At the balance sheet date, the company had net liabilities of £7,893,091.

The parent undertaking and ultimate parent undertaking have confirmed that they will provide further financial support to the company as required to enable it to meet its liabilities as and when they fall due for at least twelve months from the date of approval of the financial statements of the company. Consequently, the financial statements have been prepared on a going concern basis.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets
Amortisation is provided at the following annual rate in order to write off each asset over its estimated useful life.

Intellectual Property - 25% on cost

Research & development costs
Where research and development costs are capitalised, amortisation is provided at the following annual rate in order to write off each asset over its estimated useful life.

Research and development costs - between 10% and 20% on cost

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Improvements to property - 10% on cost
Plant and machinery - 20% on cost
Fixtures and fittings - 10% on cost
Office Equipment - 25% on cost

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

SCINOMED LTD (REGISTERED NUMBER: 06509477)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 1 JANUARY 2021 TO 29 DECEMBER 2021

2. ACCOUNTING POLICIES - continued

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 5 (2020 - 4 ) .

SCINOMED LTD (REGISTERED NUMBER: 06509477)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 1 JANUARY 2021 TO 29 DECEMBER 2021

4. INTANGIBLE FIXED ASSETS
Other
intangible
assets
£   
COST
At 1 January 2021 999,858
Additions 100,610
Disposals (2,515 )
At 29 December 2021 1,097,953
AMORTISATION
At 1 January 2021 277,967
Charge for period 104,653
Eliminated on disposal (2,515 )
At 29 December 2021 380,105
NET BOOK VALUE
At 29 December 2021 717,848
At 31 December 2020 721,891

5. TANGIBLE FIXED ASSETS
Improvements Fixtures
to Plant and and Office
property machinery fittings Equipment Totals
£    £    £    £    £   
COST
At 1 January 2021 1,579 845,026 18,934 28,172 893,711
Additions - 1,224,442 - 8,215 1,232,657
Disposals - (1,983,604 ) - - (1,983,604 )
At 29 December 2021 1,579 85,864 18,934 36,387 142,764
DEPRECIATION
At 1 January 2021 1,579 151,905 5,968 22,917 182,369
Charge for period - 190,794 1,611 2,685 195,090
Eliminated on disposal - (311,780 ) - - (311,780 )
At 29 December 2021 1,579 30,919 7,579 25,602 65,679
NET BOOK VALUE
At 29 December 2021 - 54,945 11,355 10,785 77,085
At 31 December 2020 - 693,121 12,966 5,255 711,342

SCINOMED LTD (REGISTERED NUMBER: 06509477)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 1 JANUARY 2021 TO 29 DECEMBER 2021

6. FIXED ASSET INVESTMENTS
Shares in Interest
group in joint
undertakings venture Totals
£    £    £   
COST
At 1 January 2021
and 29 December 2021 29,832 1,783,013 1,812,845
NET BOOK VALUE
At 29 December 2021 29,832 1,783,013 1,812,845
At 31 December 2020 29,832 1,783,013 1,812,845

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2021 2020
£    £   
Trade debtors 45,752 673,271
Amounts owed by group undertakings 3,505,499 2,558,066
Other debtors 403,683 299,285
3,954,934 3,530,622

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2021 2020
£    £   
Trade creditors 855,308 944,123
Taxation and social security 96,567 164,661
Other creditors 205,751 206,530
1,157,626 1,315,314

9. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2021 2020
£    £   
Amounts owed to group undertakings 18,401,701 16,224,528

The loans are unsecured with no set repayment date. A market rate of interest is payable on the loans.

SCINOMED LTD (REGISTERED NUMBER: 06509477)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 1 JANUARY 2021 TO 29 DECEMBER 2021

10. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was qualified on the following basis:

Basis for qualified opinion
We were not appointed as auditor of the company until after 31 December 2020 and thus did not observe the counting of physical inventories at the end of the year. We were unable to satisfy ourselves by alternative means concerning the inventory quantities held at 31 December 2020, which are included in the balance sheet at £1,122,529, by using other audit procedures. Consequently, we were unable to determine whether any adjustment to this amount was necessary.

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

Matters required to report by exception
Arising solely from the limitations on the scope of our work relating to inventory, referred to above:
- we have not obtained all the information and explanations that we considered necessary for the purpose of our audit.

We have nothing to report in respect of the following matters where the Companies Act requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made.
- the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemption from the requirement to prepare a Strategic Report or in preparing the Report of the Directors.

Graham French (Senior Statutory Auditor)
for and on behalf of DSC Accountants Ltd

11. POST BALANCE SHEET EVENTS

In 2022 the company acquired the remaining 50% in its Chinese Joint Venture, Scinomed (Shanghai) Bio-Tech Co. Ltd. The company is now a 100% subsidiary of Scinomed Limited.

12. ULTIMATE CONTROLLING PARTY

The controlling party is International Investments II Limited, a company incorporated in Hong Kong.